Roche: J.P. Morgan Healthcare Conference (Roche, 35th Annual J.P. Morgan Healthcare Conference) - Jan 11, 2017 - Anticipated data from P1 trial (NCT01688206) of Tecentriq in combination with vanucizumab for solid tumors in 2017; Anticipated data from P2 IMmotion 150 trial (NCT01984242) of Tecentriq in combination with Avastin for 1L RCC in 2017; Anticipated data from P3 IMpower 150 trial (NCT02366143) in 1L non-squamous NSCLC in Q3 2017
Anticipated P1 data • Anticipated P2 data • Anticipated P3 data • Biosimilar • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma
|